Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

March 2, 2021

Study Completion Date

March 2, 2021

Conditions

Atopic Dermatitis

Interventions

DRUG

LEO 138559

LEO 138559 is a compound in development at LEO Pharma A/S

DRUG

LEO 138559 placebo

Trial Locations (3)

Investigational site, Leeds

Investigational site, Liverpool

LEO Pharma investigational site, Manchester